Emgality (Galcanezumab-gnlm) for Migraine

Overview
Emgality is approved by the Food and Drug Administration (FDA) to prevent migraine in adults. Emgality is also referred to by its drug name, Galcanezumab-gnlm.

Emgality is a biologic drug – a genetically engineered antibody, or protein used by the immune system to identify and neutralize substances. Emgality is also a member of a new class of drugs called calcitonin gene-related peptide receptor (CGRP-R) antagonists. Emgality is believed to work by interfering with CGRP, a substance that dilates blood vessels and contributes to pain signals and inflammation.

How do I take it?
Prescribing information states that Emgality is administered as a subcutaneous injection once a month after initial loading doses.

Emgality comes in prefilled, single-dose syringes and pens.

Side effects
The FDA-approved label for Emgality lists injection site reactions as a common side effect.

Because Emgality is a new drug, its long-term effects are not yet known.

For more details about this treatment, visit:

Emgality.com – Lilly
https://www.emgality.com/

FDA Greenlights Galcanezumab (Emgality) for Migraine Prevention – Medscape
https://www.medscape.com/viewarticle/902676